Clin Pediatr Hematol Oncol.  2014 Oct;21(2):65-70. 10.0000/cpho.2014.21.2.65.

The Effect of Lupus Anticoagulant Detected in Children with Respiratory Tract Infection on in vitro Coagulation Time

• Kim YH
• Jeon IS

• KMID: 2279814
• DOI: http://doi.org/10.0000/cpho.2014.21.2.65

Abstract

BACKGROUND
This study was conducted in order to investigate the prevalence of lupus anticoagulant (LA) in children with respiratory tract infection and to evaluate the effect of LA on in vitro coagulation time.
METHODS
This study included 46 subjects, showing positivity to Mycoplasma pneumoniae (MP) IgM antibody and 37 subjects positive to various respiratory viruses (RV). The titer of LA and PT/aPTT were examined and investigated the effect of LA on PT/aPTT.
RESULTS
None of the subjects showed any evidence of bleeding or thrombosis during conduct of the study. Positive LA (LA titer> or =1.34) was significantly more frequent in MP group (39.1%) than RV group (18.9%)(P<0.05). Total prevalence of positive LA was 30.1%, among them 22.9% was low positive LA (1.34< or =LA<2.0) and 7.2% was high positive LA (LA> or =2.0). Low LA positive group showed only mild PT prolongation (13.00.05). All subjects of high LA positive group showed severe prolongation of aPTT (> or =60 sec), however, severe PT prolongation (> or =20 sec) was not noticed.
CONCLUSION
The prevalence of LA was relatively high in children with respiratory tract infection, however, most of them are mildly elevated. Low LA positivity was related to the mild prolongation of PT. But high LA positivity markedly prolongs the aPTT without marked prolongation of PT.

Keyword

Mycoplasma pneumoniae; Respiratory virus; Lupus anticoagulant; Coagulation time

MeSH Terms

Child*
Hemorrhage
Humans
Immunoglobulin M
Lupus Coagulation Inhibitor*
Mycoplasma pneumoniae
Pneumonia, Mycoplasma
Prevalence
Respiratory Tract Infections*
Thrombosis
Immunoglobulin M
Lupus Coagulation Inhibitor